Literature DB >> 28034844

Solanezumab and the amyloid hypothesis for Alzheimer's disease.

David G Le Couteur1, Sally Hunter2, Carol Brayne2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 28034844     DOI： 10.1136/bmj.i6771

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  20 in total

Review 1.  Antiaging Therapies, Cognitive Impairment, and Dementia.

Authors:  Devin Wahl; Rozalyn M Anderson; David G Le Couteur
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-09-16       Impact factor: 6.053

Review 2.  Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications.

Authors:  Hsin-Pei Shih; Xiaodan Zhang; Alex M Aronov
Journal:  Nat Rev Drug Discov       Date:  2017-10-27       Impact factor: 84.694

Review 3.  Peptide regulation of cofilin activity in the CNS: A novel therapeutic approach for treatment of multiple neurological disorders.

Authors:  Alisa E Shaw; James R Bamburg
Journal:  Pharmacol Ther       Date:  2017-02-20       Impact factor: 12.310

Review 4.  Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease.

Authors:  S Hunter; C Brayne
Journal:  Mol Psychiatry       Date:  2017-11-07       Impact factor: 15.992

Review 5.  EFAD transgenic mice as a human APOE relevant preclinical model of Alzheimer's disease.

Authors:  Leon M Tai; Deebika Balu; Evangelina Avila-Munoz; Laila Abdullah; Riya Thomas; Nicole Collins; Ana Carolina Valencia-Olvera; Mary Jo LaDu
Journal:  J Lipid Res       Date:  2017-04-07       Impact factor: 5.922

6.  Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.

Authors:  Jonas Elias Schweig; Hailan Yao; David Beaulieu-Abdelahad; Ghania Ait-Ghezala; Benoit Mouzon; Fiona Crawford; Michael Mullan; Daniel Paris
Journal:  Acta Neuropathol Commun       Date:  2017-09-06       Impact factor: 7.801

7.  Development of a Label-Free Immunosensor for Clusterin Detection as an Alzheimer's Biomarker.

Authors:  Kamrul Islam; Samar Damiati; Jagriti Sethi; Ahmed Suhail; Genhua Pan
Journal:  Sensors (Basel)       Date:  2018-01-20       Impact factor: 3.576

Review 8.  Alzheimer's disease drug development pipeline: 2017.

Authors:  Jeffrey Cummings; Garam Lee; Travis Mortsdorf; Aaron Ritter; Kate Zhong
Journal:  Alzheimers Dement (N Y)       Date:  2017-05-24

9.  Anticoagulants inhibit proteolytic clearance of plasma amyloid beta.

Authors:  Lu Yang; Arup Bhattacharya; Yun Li; Yuesheng Zhang
Journal:  Oncotarget       Date:  2017-12-27

10.  Rationale, study design and implementation of the LUCINDA Trial: Leuprolide plus Cholinesterase Inhibition to reduce Neurologic Decline in Alzheimer's.

Authors:  Tracy Butler; Judith D Goldberg; James E Galvin; Thomas Maloney; Lisa Ravdin; Lidia Glodzik; Mony J de Leon; Tsivia Hochman; Richard L Bowen; Craig S Atwood
Journal:  Contemp Clin Trials       Date:  2021-06-22       Impact factor: 2.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.